OTCMKTS:KYKOF

Kyowa Kirin - KYKOF Stock Forecast, Price & News

$20.87

0.00 (0.00%)

(As of 03/21/2023 12:00 AM ET)

Add

Compare

Today's Range: $20.87
▼
$20.87
50-Day Range: $20.87
▼
$22.85
52-Week Range: $20.87
▼
$23.85

Volume: 17 shs
Average Volume: 225 shs
Market Capitalization: N/A

P/E Ratio: 0.61
Dividend Yield: 95.54%
Price Target: N/A

About Kyowa Kirin (OTCMKTS:KYKOF) Stock

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Receive KYKOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kyowa Kirin and its competitors with MarketBeat's FREE daily newsletter.

KYKOF Stock News Headlines

February 9, 2023 | msn.com

Earnings Season Results Deflate Tokyo Shares

February 8, 2023 | msn.com

Fed Chief's Commentary Churns Asian Stock Markets

March 22, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

February 7, 2023 | seekingalpha.com

Kyowa Kirin Co., Ltd. GAAP EPS of ¥99.66, revenue of ¥398.37M

December 6, 2022 | finance.yahoo.com

MEI Pharma, Kyowa Kirin Cull Development Of Blood Cancer Drug Outside Japan, Look For Strategic Alternatives

December 5, 2022 | benzinga.com

MEI Pharma, Kyowa Kirin Earlier Announced Discontinuation Of Zandelisib Development Outside Of Japan Following Recent FDA Meeting

December 5, 2022 | finance.yahoo.com

MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

November 24, 2022 | finance.yahoo.com

Grünenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio

March 22, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

November 3, 2022 | finance.yahoo.com

New Effort Sheds Light on Burdens and Benefits of Parkinson's Care Partner Experience, Offers Insights for Navigating Journey

October 31, 2022 | finance.yahoo.com

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan

September 23, 2022 | finance.yahoo.com

Kyowa Kirin Co., Ltd. (4151.T)

September 16, 2022 | investing.com

Kyowa Kirin Co Ltd (4151)

June 30, 2022 | seekingalpha.com

Kyowa Kirin expands license pact with Synaffix

June 26, 2022 | finance.yahoo.com

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA® (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

June 16, 2022 | finance.yahoo.com

Japan’s Kyowa Kirin Eying $1 Billion Sale of Pharma Assets

June 10, 2022 | finance.yahoo.com

MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress

June 8, 2022 | finance.yahoo.com

Kyowa Kirin to Host Expert Roundtable Addressing Racial Health Inequities in Cancer Care

June 4, 2022 | finance.yahoo.com

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

May 26, 2022 | finance.yahoo.com

MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022

May 16, 2022 | seekingalpha.com

MEI Pharma to restate financials after errors in revenue recognition

March 25, 2022 | seekingalpha.com

MEI Pharma posts a historic drop as setback to cancer drug draws downgrades

January 18, 2022 | finance.yahoo.com

La Jolla Institute renews longtime collaboration with Kyowa Kirin, Inc.

January 7, 2022 | nasdaq.com

Kyowa Kirin Co. Ltd. (KYKOF)

January 4, 2022 | finance.yahoo.com

CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO® FROM KYOWA KIRIN NORTH AMERICA

September 27, 2021 | finance.yahoo.com

Kyowa Kirin North America Appoints Paula Soteropoulos to Board of Directors

September 24, 2021 | finance.yahoo.com

Long-Term CRYSVITA® ▼ (burosumab) Treatment Reduces the Burden of Disease in Adults With X-Linked Hypophosphataemia (XLH), a Rare Genetic Metabolic Bone Disease

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive KYKOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kyowa Kirin and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Drug Manufacturers - General
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:KYKOF
CUSIP: N/A
CIK: N/A
Web: www.kyowakirin.com
Phone: (135) 205-7200
Fax: N/A
Employees: 5,752
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 0.61
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

Masashi Miyamoto
President, CEO & Representative Director

Motohiko Kawaguchi
Executive Officer, Manager-Accounting & Finance

Mitsuo Satoh
Executive Officer, GM-Research & Development

Yutaka Osawa
Representative Director & Executive Vice President

Hiroshi Sugitani
Executive Officer & General Manager-Sales

Key Competitors

View All Competitors

KYKOF Stock - Frequently Asked Questions

Should I buy or sell Kyowa Kirin stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kyowa Kirin in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KYKOF shares.
View KYKOF analyst ratings or view top-rated stocks.
How have KYKOF shares performed in 2023?: Kyowa Kirin's stock was trading at $22.2840 at the start of the year. Since then, KYKOF stock has decreased by 6.3% and is now trading at $20.87.
View the best growth stocks for 2023 here.
Are investors shorting Kyowa Kirin?: Kyowa Kirin saw a decline in short interest in February. As of February 28th, there was short interest totaling 765,100 shares, a decline of 21.6% from the February 13th total of 976,500 shares. Based on an average daily trading volume, of 400 shares, the days-to-cover ratio is presently 1,912.8 days.
View Kyowa Kirin's Short Interest.
Is Kyowa Kirin a good dividend stock?: Kyowa Kirin (OTCMKTS:KYKOF) pays an annual dividend of $19.94 per share and currently has a dividend yield of 1.56%. The dividend payout ratio is 58.08%. This payout ratio is at a healthy, sustainable level, below 75%.

What is Kyowa Kirin's stock symbol?: Kyowa Kirin trades on the OTCMKTS under the ticker symbol "KYKOF."
How do I buy shares of Kyowa Kirin?: Shares of KYKOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kyowa Kirin's stock price today?: One share of KYKOF stock can currently be purchased for approximately $20.87.
How many employees does Kyowa Kirin have?: The company employs 5,752 workers across the globe.
How can I contact Kyowa Kirin?: Kyowa Kirin's mailing address is Otemachi Financial City Grand Cube, Tokyo, 100-0004. The official website for the company is www.kyowakirin.com. The company can be reached via phone at (135) 205-7200.

This page (OTCMKTS:KYKOF) was last updated on 3/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial